ImCheck Therapeutics ^Partner

ImCheck Therapeutics is a biotechnology company based in Marseille, France, founded in 2015 as a spinoff from the Paoli-Calmettes Cancer Institute. The company focuses on developing innovative antibody therapeutics in immuno-oncology, specifically targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. Their lead program, ICT01, is a first-in-human gamma-delta T cell-activating antibody that has shown promising results in clinical trials for various cancer types.

The company has raised approximately $186 million to date, including a recent $103 million financing round, demonstrating strong investor confidence in its vision. ImCheck Therapeutics actively presents its research at major conferences, showcasing updated efficacy data for ICT01, particularly in acute myeloid leukemia (AML). With operations in both Europe and the US, ImCheck is well-positioned to advance its clinical programs and contribute to the global biotechnology market.